Barbara Burtness, MD

Articles by Barbara Burtness, MD

Role for Afatinib in p16-Negative Head and Neck Cancer?

June 11th 2017

This video reviews results of LUX-Head & Neck 2, a randomized phase III trial that studied afatinib as adjuvant therapy in patients with unresected squamous cell head and neck cancer.

Latest Updated Articles

Role for Afatinib in p16-Negative Head and Neck Cancer?
Published: June 11th 2017 | Updated:

Barbara Burtness, MD

Articles by Barbara Burtness, MD

Role for Afatinib in p16-Negative Head and Neck Cancer?

Latest Updated Articles

Trending on CGTlive®

Regeneron’s Gene Therapy DB-OTO Improves Speech Perception in Children With Otoferlin-Related Hearing Loss

Myrtelle’s Canavan Disease Gene Therapy Effects Significant Decrease in CSF NAA and Increases in Brain Myelin Volume